Twynsta (telmisartan;amlodipine)
- Region
- 🇪🇺 EU
- Active substance
- telmisartan;amlodipine
- Company
- Boehringer Ingelheim International GmbH
- Status
- Authorised
- Therapeutic area
- Hypertension
- EU approval
- Thu 07 Oct 2010
- Application
- EMEA/H/C/001224
- ATC
- C09DB04
- Official record
- www.ema.europa.eu
Indication
Treatment of essential hypertension in adults: Add-on therapy Twynsta is indicated in adults whose blood pressure is not adequately controlled on amlodipine. Replacement therapy Adult patients receiving telmisartan and amlodipine from separate tablets can instead receive tablets of Twynsta containing the same component doses.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Onduarp Withdrawn · Boehringer Ingelheim International GmbH
Follow Twynsta
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.